



Clinical Laserthermia Systems AB Raises SEK 20.9 Million Through Full Subscription of Warrants of Series TO 8 B

NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION, OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Lund, Sweden, 30 September 2025, Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that all 5,500,000 warrants of series TO 8B, issued in connection with the directed share issue in February 2025, have been exercised. The exercise adds SEK 20.9 million before transaction costs to CLS, corresponding to a subscription rate of 100 percent.

Together with the approximately SEK 16 million raised in February, CLS has now secured the full SEK 37 million financing package, before transaction costs, originally communicated. This strengthens the Company's financial position and supports the continued execution of its growth strategy.

Comment from the CEO

"We are very pleased with the strong support demonstrated by the full subscription of shares through the TO8B and thank the warrant holders for their continued trust in CLS. With the combined proceeds received in February and now in September, CLS has secured the financing needed to accelerate commercialization of our product offerings, with focus on our partnership in neurosurgery, and move closer to sustainable profitability," comments Dan J. Mogren, CEO of CLS.

Use of proceeds

The proceeds will be used in line with the strategy adopted earlier this year, to:

- Accelerate commercialization of CLS's minimally invasive laser technology, with focus on the company's strategic partnership in neurosurgery.
- Ensure operational capacity and reinforce the supply chain.
- Advance product improvements and obtain additional regulatory approvals.
- Support the company's path towards sustainable growth and profitability.

The Warrants of series TO 8B

Each warrant of series TO 8B entitled the holder to subscribe for one (1) new B share in CLS at a subscription price of SEK 3.80. The exercise period ran from 15 to 26 September 2025.

Following registration of the newly subscribed shares with the Swedish Companies Registration Office (Bolagsverket), the total number of shares in CLS will amount to 31,166,594, corresponding to a share capital of approximately SEK 71,981,747.85

Advisors

Redeye AB acted as financial adviser, Foyen Advokatfirma as legal adviser, and Nordic Issuing as issuer agent.

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-post: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

Important Information

The publication, announcement, or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in jurisdictions where this press release has been published or distributed should inform themselves of and comply with such restrictions. Recipients of this press release are responsible for using this press release and the information herein in accordance with applicable legislation in each jurisdiction. This press release does not constitute an offer, or invitation to acquire or subscribe for any securities in the Company in any jurisdiction, neither from the Company, Redeye, nor anyone else.

This press release does not identify or purport to identify risks (direct or indirect) that may be attributed to an investment in the new shares. Any investment decision in connection with the Issue must be made based on all publicly available information regarding the Company and the Company's shares. Such information has not been independently verified by Redeye. The information in this press release is only provided as background material and does not claim to be complete. An investor should not rely solely on the information in this press release or its accuracy or completeness. Redeye is acting for the Company in connection with the transaction and not for anyone else. Redeye is not responsible to anyone other than the Company for providing the protections afforded to their clients or for giving advice in relation to the transaction or any other matter referred to herein.

This press release does not constitute a recommendation for any investors' decisions regarding the Issue. Each investor or potential investor should conduct their own investigation, analysis, and evaluation of the business and the information described in this press release and all publicly available information. The price and value of securities can decrease as well as increase. Achieved results do not constitute guidance for future results.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be offered or sold in the United States without being registered or exempted from (or in a transaction not subject to) registration under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), and applicable state laws, or to any person who is not a qualified institutional buyer (as defined in the U.S. Investment Company Act of 1940 (the "**Investment Company Act**")). The securities referred to herein may not be sold under circumstances that would require the Company to register under the Investment Company Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Furthermore, the Company has not been and will not be registered under the Investment Company Act. The information in this press release may not be announced, published, copied, or distributed, directly or indirectly, wholly or partly, in or to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia,

Belarus, or any other jurisdiction where the announcement, publication, or distribution of the information would not comply with applicable laws and regulations or would require a prospectus, registration, or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws.

This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129, (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. The Company has not approved any offer to the public of shares or rights in any member state ("**Member State**") of the European Economic Area ("**EEA**") and no prospectus has been prepared or will be prepared in connection with the Issue. In each EEA Member State, this announcement is directed only at "qualified investors" in that Member State as defined in the Prospectus Regulation.

In the United Kingdom, this press release and any other material related to the securities described herein are only distributed and directed to, and any investment or investment activity to which this document relates is available only to: (i) persons with professional experience in matters related to investments falling within the definition of "investment professionals" in Article 19.5 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) persons falling within Article 43 of the Order or high net worth entities falling within Article 49.2 (a)-(d) of the Order, or to other persons to whom it may otherwise lawfully be communicated in accordance with an exemption from Article 21.1 of the UK Financial Services and Markets Act 2000 or otherwise under circumstances where it does not apply (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this press release relates is only available to, and will only involve, relevant persons. Persons who are not relevant persons should not take any action based on this press release and should not act or rely on it. This press release is not a prospectus under the meaning of Regulation (EU) 2017/1129 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (the "**UK Prospectus Regulation**").

Forward-looking Statements

This press release contains forward-looking statements that reflect the Company's intentions, assessments, or current expectations about and goals for the Company's future operations, financial situation, development, liquidity, results, prospects, expected growth, strategies, and opportunities, as well as markets in which the Company operates. Forward-looking statements are statements that are not historical facts and that can be identified by terms such as "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "should," "could," "aim," or "might" or, in each case, their negative, or similar, expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot give any assurances that they will occur or prove to be correct. As these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcomes could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, unexpected events, and other important factors could cause actual events to differ materially from the expectations expressed or implied herein by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and accepts no responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Readers of this press release should not unduly rely on the forward-looking statements in this press release. The information, opinions, and forward-looking statements included in this press release are provided only as of the date of this press release and may be subject to change without notice. Neither the Company nor anyone else undertakes any obligation to review, update, confirm, or announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-09-2025 13:35 CET.